Incannex Receives HREC Approval For Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis
Portfolio Pulse from Vuk Zdinjak
Incannex Healthcare Limited (NASDAQ:IXHL) has received approval from Bellberry Human Research Ethics Committee for its phase 2 clinical trial of IHL-675A, a CBD-based drug for rheumatoid arthritis. The trial will assess the efficacy, safety, and tolerability of IHL-675A compared to CBD and hydroxychloroquine sulphate, and placebo. The study will be managed by Avance Clinical and will include 128 participants across 8-10 sites in Australia and New Zealand.
July 13, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Incannex Healthcare's approval for phase 2 clinical trial of its CBD-based drug for rheumatoid arthritis could potentially boost its stock as it indicates progress in the company's product development.
The approval for the phase 2 clinical trial of Incannex's CBD-based drug for rheumatoid arthritis is a significant milestone for the company. It indicates progress in the company's product development, which could potentially attract more investors and boost its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100